BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 20866165)

  • 21. Anemia Prevalence, Type, and Associated Risks in a Cohort of 5.0 Million Insured Patients in the United States by Level of Kidney Function.
    Farrington DK; Sang Y; Grams ME; Ballew SH; Dunning S; Stempniewicz N; Coresh J
    Am J Kidney Dis; 2023 Feb; 81(2):201-209.e1. PubMed ID: 36181996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postdialysis outcomes associated with consistent anemia treatment in predialysis patients with chronic kidney disease.
    Wish JB; Nassar GM; Schulman K; del Aguila M; Provenzano R
    Clin Nephrol; 2008 Apr; 69(4):251-9. PubMed ID: 18397699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis.
    Shepshelovich D; Rozen-Zvi B; Avni T; Gafter U; Gafter-Gvili A
    Am J Kidney Dis; 2016 Nov; 68(5):677-690. PubMed ID: 27321965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Achievement of renal anemia KDIGO targets by two different clinical strategies - a European hemodialysis multicenter analysis.
    Drozdz M; Weigert A; Silva F; Frazão J; Alsuwaida A; Krishnan M; Kleophas W; Brzosko S; Johansson FK; Jacobson SH
    BMC Nephrol; 2019 Jan; 20(1):5. PubMed ID: 30616548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Iron supplementation associates with low mortality in pre-dialyzed advanced chronic kidney disease patients receiving erythropoiesis-stimulating agents: a nationwide database analysis.
    Kuo KL; Hung SC; Liu JS; Chang YK; Hsu CC; Tarng DC
    Nephrol Dial Transplant; 2015 Sep; 30(9):1518-25. PubMed ID: 25829323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of anemia in chronic kidney disease patients: baseline findings from Chronic Kidney Disease Japan Cohort Study.
    Akizawa T; Makino H; Matsuo S; Watanabe T; Imai E; Nitta K; Ohashi Y; Hishida A;
    Clin Exp Nephrol; 2011 Apr; 15(2):248-57. PubMed ID: 21234785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data.
    Macdougall IC; White C; Anker SD; Bhandari S; Farrington K; Kalra PA; McMurray JJV; Murray H; Steenkamp R; Tomson CRV; Wheeler DC; Winearls CG; Ford I;
    Am J Nephrol; 2018; 48(4):260-268. PubMed ID: 30304714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. It's time to compare anemia management strategies in hemodialysis.
    Coyne DW
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):740-2. PubMed ID: 20299363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.
    Carrero JJ; Bárány P; Yilmaz MI; Qureshi AR; Sonmez A; Heimbürger O; Ozgurtas T; Yenicesu M; Lindholm B; Stenvinkel P
    Nephrol Dial Transplant; 2012 Feb; 27(2):709-15. PubMed ID: 21617198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol.
    Strippoli GF;
    Trials; 2010 Jun; 11():70. PubMed ID: 20534124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of Hemoglobin Cycling and Its Clinical Impact on Outcomes in Thai End-Stage Renal Disease Patients Treated with Hemodialysis and Erythropoiesis-Stimulating Agent.
    Thanakitcharu P; Jirajan B
    J Med Assoc Thai; 2016 Feb; 99 Suppl 2():S28-37. PubMed ID: 27266213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parenteral iron use: possible contribution to exceeding target hemoglobin in hemodialysis patients.
    Ibrahim HN; Foley RN; Zhang R; Gilbertson DT; Collins AJ
    Clin J Am Soc Nephrol; 2009 Mar; 4(3):623-9. PubMed ID: 19211669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents.
    Mhaskar R; Wao H; Miladinovic B; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD009624. PubMed ID: 26845108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing anemia management in hospitalized patients with end-stage renal disease.
    Heung M; Mueller BA; Segal JH
    Ann Pharmacother; 2009 Feb; 43(2):276-82. PubMed ID: 19141655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence, treatment patterns, and healthcare resource utilization in Medicare and commercially insured non-dialysis-dependent chronic kidney disease patients with and without anemia in the United States.
    St Peter WL; Guo H; Kabadi S; Gilbertson DT; Peng Y; Pendergraft T; Li S
    BMC Nephrol; 2018 Mar; 19(1):67. PubMed ID: 29544446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in the use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in patients with cancer amidst regulatory and reimbursement changes.
    Gawade PL; Berlin JA; Henry DH; Tomita D; Brooks BD; Franklin J; Bradbury BD; Critchlow CW
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1357-1366. PubMed ID: 28809079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients.
    Barbieri C; Bolzoni E; Mari F; Cattinelli I; Bellocchio F; Martin JD; Amato C; Stopper A; Gatti E; Macdougall IC; Stuard S; Canaud B
    PLoS One; 2016; 11(3):e0148938. PubMed ID: 26939055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changing patterns of anemia management in US hemodialysis patients.
    Freburger JK; Ng LJ; Bradbury BD; Kshirsagar AV; Brookhart MA
    Am J Med; 2012 Sep; 125(9):906-14.e9. PubMed ID: 22938926
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.